In recent years, clinical studies have illustrated that recombinant human thrombopoietin (rhTPO) can significantly stimulate platelet production and increase peripheral platelet counts, which is primarily used to manage chemotherapy-induced thrombocytopenia and primary immume thrombocytopenia (ITP) (Altomare et al., 2012; Rodeghiero and Carli 2017). This evidence concerns the gene THPO and Thrombocytopenia.